Diagnosis and Treatment
Serology and Immunity Tests
REli Lilly's AbCellera antibody treatment shows potency against all current COVID-19 variants.
NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership for speeding development of the most promising treatments and vaccine candidates, has launched Phase 2/3 trials for the novel fully human poly-clonal antibody therapeutic SAB-185, co-developed with SAB Biotherapeutics.
Vaccine Research Tools
The world has reached the major milestone of 1 billion COVID-19 vaccinations -- 4 months after vaccine rollout and just over a year since vaccine trials in humans began.